Chapter One Non-Neoplastic Disorders Of
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Medical Review(S) Clinical Review
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................ -
• Cytosis: O Neutrophilia: Defined As an Increase in the Neutrophilic Count in the Peripheral Blood Above Reference Range for Age
HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS-UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD NONNEOPLASTIC DISEASES OF THE WHITE BLOOD CELLS • There are five major types of WBCs in the blood: neutrophils, lymphocytes, eosinophils, basophils and monocytes. • The normal function of the white blood cells depends on a tight regulation of their count and their function. Therefore, disease develops if there is a derangement of the cells count or function, it takes one of the following forms: o Cytosis: increase in the number of circulating cells above reference range. (Note: leukocytosis means an increase in the WBC count, neutrophilia means increase in the neutrophilic count, lymphocytosis means increase in the lymphocytic count, monocytosis means increase in the monocytic count, basophilia means increase in the basophilic count and eosinophilia means in crease in the eosinophilic count). o Cytopenia: decrease in the number of circulating cells below reference range. (Note: neutropenia means decreased neutrophils, lymphocytopenia, or simply lymphopenia, means decrease in lymphocytes, monocytopenia means decrease in monocytes, eosinopenia means decrease in eosinophils, and basopenia means decrease in basophils). o Abnormal or absent function • Cytosis: o Neutrophilia: defined as an increase in the neutrophilic count in the peripheral blood above reference range for age. o Causes: bacterial infection is the most common and most important etiology. Tissue necrosis in cases of burns or trauma and medications such as epinephrine and corticosteroids are also additional causes for neutrophilia. § Some physiologic conditions can lead to neutrophilia such as stress, smoking and pregnancy. o Pathophysiology: neutrophils are present in the blood in two populations: circulating and marginal (meaning neutrophils stuck to the vessel wall). -
BLOOD CELL IDENTIFICATION Educational Commentary Is
EDUCATIONAL COMMENTARY – BLOOD CELL IDENTIFICATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click on Continuing Education on the left side of the screen. Learning Outcomes After completion of this exercise, the participant will be able to: • identify morphologic features of normal peripheral blood leukocytes and platelets. • describe characteristic morphologic findings associated with reactive lymphocytes. • compare morphologic features of normal lymphocytes, reactive lymphocytes, and monocytes. Photograph BCI-01 shows a reactive lymphocyte. The term “variant” is also used to describe these cells that display morphologic characteristics different from what is considered normal lymphocyte appearance. Reactive lymphocytes demonstrate a wide variety of morphologic features. They are most often associated with viral illnesses, so it is expected that some of these cells would be present in the peripheral blood of this patient. This patient had infectious mononucleosis that was confirmed with a positive mononucleosis screening test. An increased number of reactive lymphocytes is a morphologic hallmark of infectious mononucleosis. Some generalizations regarding the morphology of reactive lymphocytes can be made. These cells are often large with abundant cytoplasm. Cytoplasmic vacuoles and/or azurophilic granules may also be present. Reactive lymphocytes have an increased amount of RNA in the cytoplasm, which is reflected by an associated increase in cytoplasmic basophilia. The cytoplasm may stain gray, pale-blue, or a very deep blue and appear patchy. The cytoplasmic margins may be indented by surrounding red blood cells and appear a darker blue than the rest of the cytoplasm. Likewise, the nuclei in reactive lymphocytes are variably shaped and may be round, oval, indented, or lobulated. -
A Phase Ib Study Evaluating Cobimetinib Plus
Official Title: A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma NCT Number: NCT03178851 Document Date: Protocol Version 5: 26-October-2018 PROTOCOL TITLE: A PHASE IB STUDY EVALUATING COBIMETINIB PLUS ATEZOLIZUMAB IN PATIENTS WITH V600 ADVANCED BRAF WILD-TYPE MELANOMA WHO HAVE PROGRESSED DURING OR AFTER TREATMENT WITH ANTI−PD-1 THERAPY AND ATEZOLIZUMAB MONOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED V600 BRAF WILD-TYPE MELANOMA PROTOCOL NUMBER: CO39721 VERSION NUMBER: 5 EUDRACT NUMBER: 2016-004402-34 IND NUMBER: 135,717 TEST PRODUCTS: Cobimetinib (RO5514041) Atezolizumab (RO5541267) MEDICAL MONITOR: M.D. SPONSOR: F. Hoffmann-La Roche Ltd DATE FINAL: 14 December 2016 DATES AMENDED: Version 2: 23 June 2017 Version 3: 19 September 2017 Version 4: 3 February 2018 Version 5: See electronic date stamp below. PROTOCOL AMENDMENT APPROVAL Approver's Name Title Date and Time (UTC) Company Signatory 26-Oct-2018 10:19:14 CONFIDENTIAL This clinical study is being sponsored globally by F. Hoffmann-La Roche Ltd of Basel, Switzerland. However, it may be implemented in individual countries by Roche’s local affiliates, including Genentech, Inc. in the United States. The information contained in this document, especially any unpublished data, is the property of F. Hoffmann-La Roche Ltd (or under its control) and therefore is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Ethics Committee or Institutional Review Board. -
Reptile Clinical Pathology Vickie Joseph, DVM, DABVP (Avian)
Reptile Clinical Pathology Vickie Joseph, DVM, DABVP (Avian) Session #121 Affiliation: From the Bird & Pet Clinic of Roseville, 3985 Foothills Blvd. Roseville, CA 95747, USA and IDEXX Laboratories, 2825 KOVR Drive, West Sacramento, CA 95605, USA. Abstract: Hematology and chemistry values of the reptile may be influenced by extrinsic and intrinsic factors. Proper processing of the blood sample is imperative to preserve cell morphology and limit sample artifacts. Identifying the abnormal changes in the hemogram and biochemistries associated with anemia, hemoparasites, septicemias and neoplastic disorders will aid in the prognostic and therapeutic decisions. Introduction Evaluating the reptile hemogram is challenging. Extrinsic factors (season, temperature, habitat, diet, disease, stress, venipuncture site) and intrinsic factors (species, gender, age, physiologic status) will affect the hemogram numbers, distribution of the leukocytes and the reptile’s response to disease. Certain procedures should be ad- hered to when drawing and processing the blood sample to preserve cell morphology and limit sample artifact. The goal of this paper is to briefly review reptile red blood cell and white blood cell identification, normal cell morphology and terminology. A detailed explanation of abnormal changes seen in the hemogram and biochem- istries in response to anemia, hemoparasites, septicemias and neoplasia will be addressed. Hematology and Chemistries Blood collection and preparation Although it is not the scope of this paper to address sites of blood collection and sample preparation, a few im- portant points need to be explained. For best results to preserve cell morphology and decrease sample artifacts, hematologic testing should be performed as soon as possible following blood collection. -
Complete Blood Count in Primary Care
Complete Blood Count in Primary Care bpac nz better medicine Editorial Team bpacnz Tony Fraser 10 George Street Professor Murray Tilyard PO Box 6032, Dunedin Clinical Advisory Group phone 03 477 5418 Dr Dave Colquhoun Michele Cray free fax 0800 bpac nz Dr Rosemary Ikram www.bpac.org.nz Dr Peter Jensen Dr Cam Kyle Dr Chris Leathart Dr Lynn McBain Associate Professor Jim Reid Dr David Reith Professor Murray Tilyard Programme Development Team Noni Allison Rachael Clarke Rebecca Didham Terry Ehau Peter Ellison Dr Malcolm Kendall-Smith Dr Anne Marie Tangney Dr Trevor Walker Dr Sharyn Willis Dave Woods Report Development Team Justine Broadley Todd Gillies Lana Johnson Web Gordon Smith Design Michael Crawford Management and Administration Kaye Baldwin Tony Fraser Kyla Letman Professor Murray Tilyard Distribution Zane Lindon Lyn Thomlinson Colleen Witchall All information is intended for use by competent health care professionals and should be utilised in conjunction with © May 2008 pertinent clinical data. Contents Key points/purpose 2 Introduction 2 Background ▪ Haematopoiesis - Cell development 3 ▪ Limitations of reference ranges for the CBC 4 ▪ Borderline abnormal results must be interpreted in clinical context 4 ▪ History and clinical examination 4 White Cells ▪ Neutrophils 5 ▪ Lymphocytes 9 ▪ Monocytes 11 ▪ Basophils 12 ▪ Eosinophils 12 ▪ Platelets 13 Haemoglobin and red cell indices ▪ Low haemoglobin 15 ▪ Microcytic anaemia 15 ▪ Normocytic anaemia 16 ▪ Macrocytic anaemia 17 ▪ High haemoglobin 17 ▪ Other red cell indices 18 Summary Table 19 Glossary 20 This resource is a consensus document, developed with haematology and general practice input. We would like to thank: Dr Liam Fernyhough, Haematologist, Canterbury Health Laboratories Dr Chris Leathart, GP, Christchurch Dr Edward Theakston, Haematologist, Diagnostic Medlab Ltd We would like to acknowledge their advice, expertise and valuable feedback on this document. -
Anemic Syndrome and White Blood Cells Disorders
27. 11. 2020 Anemic syndrome and white blood cells disorders Kristína Repová, M.D., PhD. [email protected] Institute of Pathophysiology, Faculty of Medicine, Bratislava Prepared exclusively for the purposes of distance education at the Faculty of Medicine, Comenius University in Bratislava in 2020/21 Hematopoeisis • Hematopoietic organs: • Bone marrow: • forming of erythrocytes, granulocytes, monocytes, thrombocytes, partially lymphocytes • Thymus: • forming of T-lymphocytes • Lymphatic nodes, tonsils, spleen: • forming of B-lymphocytes lymphoid multipotent stem cell pluripotent progenitor cell precursor cell stem cell myleoid multipotent stem cell 1 27. 11. 2020 Hematopoeisis 3 Pluripotent hematopoietic stem cell (self-renewal) Myeloid multipotent Lymphoid multipotent stem cell stem cell Megacaryocyte and Granulocyte and T-cell and NK B-cell erythroid progenitor Macrophage progenitor cell progenitor progenitor Megacaryocyte Erythrocyte Granulocyte Monocyte progenitor progenitor progenitor progenitor (CFU-Meg) (CFU-E) (CFU-G) (CFU-M) Myeloblast NK-cell Proerythroblast Monoblast Lymphoblast Lymphoblast Promyelocyte Megacaryoblast Erythroblast Myelocyte Promonocyte Prolymphocyte Prolymphocyte Megacaryocyte Reticulocyte Metamyelocyte Monocyte T-cell B-cell Thrombocyte Erythrocyte Band cell Basophil Eosinophil Macrophage Dendritic cell Neutrophil 2 27. 11. 2020 I. Disorders of red blood cells II. Disorders of white blood cells III. Myeloproliferative and lymphoproliferative disorders I. Disorders of red blood cells 1. Anemia 2. -
CDG and Immune Response: from Bedside to Bench and Back Authors
CDG and immune response: From bedside to bench and back 1,2,3 1,2,3,* 2,3 1,2 Authors: Carlota Pascoal , Rita Francisco , Tiago Ferro , Vanessa dos Reis Ferreira , Jaak Jaeken2,4, Paula A. Videira1,2,3 *The authors equally contributed to this work. 1 Portuguese Association for CDG, Lisboa, Portugal 2 CDG & Allies – Professionals and Patient Associations International Network (CDG & Allies – PPAIN), Caparica, Portugal 3 UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal 4 Center for Metabolic Diseases, UZ and KU Leuven, Leuven, Belgium Word count: 7478 Number of figures: 2 Number of tables: 3 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/jimd.12126 This article is protected by copyright. All rights reserved. Abstract Glycosylation is an essential biological process that adds structural and functional diversity to cells and molecules, participating in physiological processes such as immunity. The immune response is driven and modulated by protein-attached glycans that mediate cell-cell interactions, pathogen recognition and cell activation. Therefore, abnormal glycosylation can be associated with deranged immune responses. Within human diseases presenting immunological defects are Congenital Disorders of Glycosylation (CDG), a family of around 130 rare and complex genetic diseases. In this review, we have identified 23 CDG with immunological involvement, characterised by an increased propensity to – often life-threatening – infection. -
Severe Congenital Neutropenia with Monocytosis and Non-Syndromic Sensorineural Hear
Venugopal et al. BMC Medical Genetics (2020) 21:35 https://doi.org/10.1186/s12881-020-0971-z RESEARCH ARTICLE Open Access Two monogenic disorders masquerading as one: severe congenital neutropenia with monocytosis and non-syndromic sensorineural hearing loss Parvathy Venugopal1,2†, Lucia Gagliardi1,2,3,4,5†, Cecily Forsyth6†, Jinghua Feng7,8, Kerry Phillips9, Milena Babic1,2, Nicola K. Poplawski9, Hugh Young Rienhoff Jr10, Andreas W. Schreiber2,7,8,11, Christopher N. Hahn1,2,3,8†, Anna L. Brown1,2,8† and Hamish S. Scott1,2,3,7,8*† Abstract Background: We report a large family with four successive generations, presenting with a complex phenotype of severe congenital neutropenia (SCN), partially penetrant monocytosis, and hearing loss of varying severity. Methods: We performed whole exome sequencing to identify the causative variants. Sanger sequencing was used to perform segregation analyses on remaining family members. Results: We identified and classified a pathogenic GFI1 variant and a likely pathogenic variant in MYO6 which together explain the complex phenotypes seen in this family. Conclusions: We present a case illustrating the benefits of a broad screening approach that allows identification of oligogenic determinants of complex human phenotypes which may have been missed if the screening was limited to a targeted gene panel with the assumption of a syndromic disorder. This is important for correct genetic diagnosis of families and disentangling the range and severity of phenotypes associated with high impact variants. Keywords: Neutropenia, Congenital neutropenia, Leukemia predisposition, Polygenic inheritance, Hearing loss Background cases [2]. It may also occur as a part of a syndrome with Severe congenital neutropenia (SCN) was first described other developmental defects (e.g. -
The Significance of Various Granulocytic Inclusions
4/8/19 THE SIGNIFICANCE OF VARIOUS DISCLOSURES GRANULOCYTIC INCLUSIONS ¡ No relevant financial interests to disclose. KRISTLE HABERICHTER, DO, FCAP GRAND TRAVERSE PATHOLOGY, PLLC OBJECTIVES GRANULOCYTES ¡ Innate immune system ¡ Travel to sites of infection, recognize and phagocytose pathogens ¡ Recognize common and uncommon granulocytic inclusions, including those associated with certain ¡ Utilize numerous cytotoxic mechanisms to kill pathogens inherited disorders and infectious etiologies ¡ Granulopoiesis occurs in the bone marrow ¡ Sufficient stem cells, adequate microenvironment, and regulatory factors ¡ Identify newly described green neutrophilic inclusions ¡ Granulocyte colony stimulating factor (G-CSF) → Granulocytes ¡ Monocyte colony stimulating factor (M-CSF) → Monocytes ¡ Understand the clinical significance and implications of various inclusions ¡ Granulocyte-monocytes colony stimulating factor (GM-CSF) → Granulocytes & Monocytes ¡ 1-3 weeks for complete granulopoiesis to occur ¡ Neutrophils only circulate for a few hours before migrating to the tissues Photo by K. Haberichter (Giemsa, 1000x) GRANULOCYTES INCLUSION CATEGORIES ¡ Primary granules → Myeloperoxidase Reactive/Acquired Changes Congenital Abnormalities Infectious Etiologies ¡ “Late” myeloblasts and promyelocytes ¡ To x ic G r a n u la t io n ¡ Chédiak-Higashi Syndrome ¡ Anaplasma ¡ Secondary granules → Leukocyte alkaline phosphatase ¡ Döhle Bodies ¡ Alder-Reilly Anomaly ¡ Ehrlichia ¡ Myelocytes, metamyelocytes, band and segmented neutrophils ¡ Cytokine Effect ¡ May-Hegglin -
Trapped Neutrophil Syndrome in a Border Collie Dog: Clinical, Clinico-Pathologic, and Molecular Findings
NOTE Internal Medicine Trapped Neutrophil Syndrome in a Border Collie Dog: Clinical, Clinico-Pathologic, and Molecular Findings Keijiro MIZUKAMI1), Tomoaki SHOUBUDANI2), Seira NISHIMOTO2), Ryuta KAWAMURA2), Akira YABUKI1) and Osamu YAMATO1)* 1)Laboratory of Clinical Pathology, Department of Veterinary Medicine, Kagoshima University, 1–21–24 Kohrimoto, Kagoshima 890–0065, Japan 2)Athena Pet Care Clinic, 3 Tamaike-cho, Nishi-ku, Nagoya 452–0812, Japan (Received 21 October 2011/Accepted 27 December 2011/Published online in J-STAGE 12 January 2012) ABSTRACT. Trapped neutrophil syndrome (TNS) is an autosomal recessive inherited neutropenia known in Border Collies since the 1990’s. Recently, the causative mutation has been identified in the canine VPS13B gene and a DNA-based diagnosis has now become available. The present paper describes clinical and clinico-pathologic findings in a Border Collie with TNS that was molecularly diag- nosed for the first time in Japan. In a 10-week-old male Border Collie with microgenesis and symptoms related to recurrent infections, a hematological examination revealed severe leukopenia due to neutropenia, suggesting the dog to be affected by inherited neutro- penic immunodeficiency. Direct DNA sequencing demonstrated that the dog was homozygous for the causative mutation of TNS and both its parents were heterozygous carriers. In addition, a simple and rapid polymerase chain reaction-based length polymorphism analysis coupled with microchip electrophoresis was developed for the genotyping of TNS. This assay could discriminate clearly all genotypes, suggesting that it was suitable for both individual diagnosis and large-scale surveys for prevention. KEY WORDS: Border Collie dog, Cohen syndrome, neutropenia, trapped neutrophil syndrome. -
Plate 1. Photomicrographs of Leukocyte Abnormalities (All Blood Films Stained with Wright Stain) (5 Mm Bar in L Applies to Each Frame)
Plate 1. Photomicrographs of leukocyte abnormalities (all blood films stained with Wright stain) (5 mm bar in L applies to each frame). A. Toxic band neutrophil with foamy cytoplasm that contains Döhle bodies, horse. B. Toxic neutrophil, dog. C. Toxic giant neutrophil with double nucleus and toxic band neutrophil, cat. D. Hypersegmented neutrophil, horse. E. Reactive lymphocyte, dog. F. Reactive lymphocyte, dog. G. Reactive lymphocyte, horse. H. Reactive plasmacytoid lymphocyte, cat. I. Activated monocyte or macrophage, cat. J. Sideroleukocyte, dog. K. Erythrophage, foal with neonatal isoerythrolysis. L. Neutrophil containing bacterial bacilli, cat. Plate 2. Photomicrographs of leukocyte abnormalities (all Wright-stained blood films unless otherwise stated) (5 mm bar in L applies to each frame). A. Morula of Ehrlichia ewingii in a neutrophil, dog. B. Morulae of Anaplasma phagocytophilum in a neutrophil, horse (from ASVCP slide contributed by J.W. Harvey, 1983). C. Morula of Ehrlichia canis in a granular lymphocyte, Panótico Rápido dip stain, Brazilian dog, (blood film courtesy of Camilo Bulla, Michigan State University). D. Distemper inclusions in a neutrophil, dog (from ASVCP slide contributed by J.C. Tobey, 1993). E. Gametocyte of Hepatozoon americanum in a monocyte, dog (from ASVCP slide contributed by C.J. LeBlanc et al., 2002). F. Yeast stages of Histoplasma capsulatum in a neutrophil, cat. G. Negative-staining Mycobacterium sp. in a neutrophil, dog (from ASVCP slide contributed by H.W. Tvedten, 1988). H. Negative-stain- ing Mycobacterium sp. in a monocyte, dog (from same slide as G). I. Tachyzoites of Toxoplasma gondii in a neutrophil, dog. J. Pelger-Huët neutrophil, dog. K.